相似文献
1
Complement activation and cardiac surgery: a novel target for improving outcomes.
Anesth Analg. 2012 Oct;115(4):759-71. doi: 10.1213/ANE.0b013e3182652b7d. Epub 2012 Jul 13.
2
Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.
Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):145-52. doi: 10.2174/157489008784705322.
3
Controlling the complement system in inflammation.
Immunopharmacology. 1997 Dec;38(1-2):51-62. doi: 10.1016/s0162-3109(97)00057-x.
4
Applying complement therapeutics to rare diseases.
Clin Immunol. 2015 Dec;161(2):225-40. doi: 10.1016/j.clim.2015.08.009. Epub 2015 Sep 1.
5
Therapeutic potential of complement modulation.
Nat Rev Drug Discov. 2010 Jan;9(1):43-56. doi: 10.1038/nrd3011. Epub 2009 Dec 4.
6
Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery.
Clin Exp Immunol. 2016 May;184(2):257-63. doi: 10.1111/cei.12763. Epub 2016 Feb 8.
7
C1 esterase inhibitor in pediatric cardiac surgery with cardiopulmonary bypass plays a vital role in activation of the complement system.
Heart Vessels. 2020 Jan;35(1):46-51. doi: 10.1007/s00380-019-01466-2. Epub 2019 Jul 5.
8
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Ann Thorac Surg. 2004 Mar;77(3):942-9; discussion 949-50. doi: 10.1016/j.athoracsur.2003.08.054.
9
The possible role of complement activation in Alzheimer disease.
Trends Mol Med. 2002 Nov;8(11):519-23. doi: 10.1016/s1471-4914(02)02422-x.
10
Therapeutic complement inhibition: new developments.
Semin Thromb Hemost. 2010 Sep;36(6):660-8. doi: 10.1055/s-0030-1262888. Epub 2010 Sep 23.
引用本文的文献
1
Vasoplegic Syndrome Following Bypass: A Comprehensive Review of Pathophysiology and Proposed Treatments.
Cureus. 2025 Jan 27;17(1):e78057. doi: 10.7759/cureus.78057. eCollection 2025 Jan.
2
The Crucial Triad: Endothelial Glycocalyx, Oxidative Stress, and Inflammation in Cardiac Surgery-Exploring the Molecular Connections.
Int J Mol Sci. 2024 Oct 10;25(20):10891. doi: 10.3390/ijms252010891.
3
High Preoperative Systemic Immune-Inflammation Index Values Significantly Predicted Poor Outcomes After on-Pump Coronary Artery Bypass Surgery.
J Inflamm Res. 2024 Feb 7;17:755-764. doi: 10.2147/JIR.S449795. eCollection 2024.
4
The Complement System: A Potential Therapeutic Target in Liver Cancer.
Life (Basel). 2022 Sep 30;12(10):1532. doi: 10.3390/life12101532.
5
Narrative review of the systemic inflammatory reaction to cardiac surgery and cardiopulmonary bypass.
Artif Organs. 2022 Apr;46(4):568-577. doi: 10.1111/aor.14171. Epub 2022 Jan 21.
6
Inflammation in Metabolic and Cardiovascular Disorders-Role of Oxidative Stress.
Life (Basel). 2021 Jul 9;11(7):672. doi: 10.3390/life11070672.
7
An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia.
Biomedicines. 2021 Mar 13;9(3):296. doi: 10.3390/biomedicines9030296.
8
Factors involved in initiation and regulation of complement lectin pathway influence postoperative outcome after pediatric cardiac surgery involving cardiopulmonary bypass.
Sci Rep. 2019 Feb 27;9(1):2930. doi: 10.1038/s41598-019-39742-w.
9
Bioactive Sphingolipids, Complement Cascade, and Free Hemoglobin Levels in Stable Coronary Artery Disease and Acute Myocardial Infarction.
Mediators Inflamm. 2018 Jul 9;2018:2691934. doi: 10.1155/2018/2691934. eCollection 2018.
10
Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury.
PLoS One. 2017 Jun 29;12(6):e0179450. doi: 10.1371/journal.pone.0179450. eCollection 2017.
本文引用的文献
1
Pathophysiology of hereditary angioedema.
Am J Rhinol Allergy. 2011 Nov-Dec;25(6):373-8. doi: 10.2500/ajra.2011.25.3661.
2
MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans.
Int J Cardiol. 2013 Jun 20;166(2):499-504. doi: 10.1016/j.ijcard.2011.11.032. Epub 2011 Dec 15.
3
Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis.
J Immunol. 2012 Jan 15;188(2):885-91. doi: 10.4049/jimmunol.1102916. Epub 2011 Dec 12.
4
Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications.
Am J Pathol. 2012 Jan;180(1):104-12. doi: 10.1016/j.ajpath.2011.09.026. Epub 2011 Nov 8.
5
The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway.
J Immunol. 2011 Oct 1;187(7):3751-8. doi: 10.4049/jimmunol.1100280. Epub 2011 Aug 24.
6
Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury.
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7523-8. doi: 10.1073/pnas.1101748108. Epub 2011 Apr 18.
7
Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity.
J Immunol. 2010 Nov 15;185(10):6096-104. doi: 10.4049/jimmunol.1002185. Epub 2010 Oct 18.
8
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
J Thorac Cardiovasc Surg. 2011 Jul;142(1):89-98. doi: 10.1016/j.jtcvs.2010.08.035. Epub 2010 Sep 28.
9
Molecular intercommunication between the complement and coagulation systems.
J Immunol. 2010 Nov 1;185(9):5628-36. doi: 10.4049/jimmunol.0903678. Epub 2010 Sep 24.
10
Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation.
Immunobiology. 2011 Jan-Feb;216(1-2):96-102. doi: 10.1016/j.imbio.2010.02.005. Epub 2010 Mar 4.
Zotero 插件